These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35110417)

  • 21. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
    Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
    Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs).
    Kim S; Kim HD; Kim EJ; Ryu MH; Kang YK
    BMC Cancer; 2024 Oct; 24(1):1245. PubMed ID: 39379868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Milhem M; Deutsch JM
    Curr Clin Pharmacol; 2015; 10(4):311-20. PubMed ID: 26548908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
    Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
    Qi J; Liu HL; Ren F; Liu S; Shi W; Liu WH; Cai GQ; Liao GQ
    World J Surg Oncol; 2020 Apr; 18(1):70. PubMed ID: 32264886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.
    Belinsky MG; Cai KQ; Zhou Y; Luo B; Pei J; Rink L; von Mehren M
    BMC Cancer; 2017 Aug; 17(1):512. PubMed ID: 28768491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
    Blay JY; Shen L; Kang YK; Rutkowski P; Qin S; Nosov D; Wan D; Trent J; Srimuninnimit V; Pápai Z; Le Cesne A; Novick S; Taningco L; Mo S; Green S; Reichardt P; Demetri GD
    Lancet Oncol; 2015 May; 16(5):550-60. PubMed ID: 25882987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.
    Toulmonde M; Blay JY; Bouche O; Mir O; Penel N; Isambert N; Duffaud F; Bompas E; Esnaud T; Boidot R; Geneste D; Ghiringhelli F; Lucchesi C; Bellera CA; Le Loarer F; Italiano A
    Clin Cancer Res; 2019 Aug; 25(15):4611-4615. PubMed ID: 30979737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Succinate dehydrogenase-deficient gastrointestinal stromal tumors.
    Wang YM; Gu ML; Ji F
    World J Gastroenterol; 2015 Feb; 21(8):2303-14. PubMed ID: 25741136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.
    Pantaleo MA; Heinrich MC; Italiano A; Valverde C; Schöffski P; Grignani G; Reyners AKL; Bauer S; Reichardt P; Stark D; Berhanu G; Brandt U; Stefanelli T; Gelderblom H
    BMC Cancer; 2022 May; 22(1):511. PubMed ID: 35524239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The management of metastatic GIST: current standard and investigational therapeutics.
    Kelly CM; Gutierrez Sainz L; Chi P
    J Hematol Oncol; 2021 Jan; 14(1):2. PubMed ID: 33402214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial.
    Verschuur AC; Bajčiová V; Mascarenhas L; Khosravan R; Lin X; Ingrosso A; Janeway KA
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):41-50. PubMed ID: 31006038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
    Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
    J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
    Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
    Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
    Yonkus JA; Alva-Ruiz R; Grotz TE
    Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
    Jones RL; Serrano C; von Mehren M; George S; Heinrich MC; Kang YK; Schöffski P; Cassier PA; Mir O; Chawla SP; Eskens FALM; Rutkowski P; Tap WD; Zhou T; Roche M; Bauer S
    Eur J Cancer; 2021 Mar; 145():132-142. PubMed ID: 33465704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.